Molecular markers of glioma: An update on recent progress and perspectives

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 12, 2012, Pages 1971-1981

  Gupta, Kirti ^a,b   Salunke, Pravin ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Diagnostics; Glioma; Molecular markers

Indexed keywords

B RAF KINASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NEUROFIBROMIN; PROCARBAZINE; TEMOZOLOMIDE; TUMOR MARKER; VINCRISTINE;

ASTROCYTOMA; BINDING AFFINITY; BRAF GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; CPG ISLAND; DECARBOXYLATION; DISEASE MARKER; DNA SYNTHESIS; DRUG SENSITIVITY; EGFR GENE; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUSION; GENE MUTATION; GENE SILENCING; GLIOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IDH1 GENE; IDH2 GENE; IDH3 GENE; MEDICAL RESEARCH; MGMT GENE; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PYROSEQUENCING; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; PATHOLOGY, MOLECULAR; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871345494     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1323-y     Document Type: Review

References (84)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
2. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
3. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 27:1275-1279
4. Cairncross G, Jenkins R (2008) Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 14:352-357
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
6. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
7. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241-252
8. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463-469
9. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro- Oncology 13:317-323
10. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
11. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastomas. Pediatr Blood Cancer 48:403-407
12. Ducray F, Criniere E, Idbaih A et al (2009) α-Internexin expression identifies 1p/19q codeleted gliomas. Neurology 72:156-161
13. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R et al (2009) Extent of MGMT promoter methylation correlates without come in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124-131
14. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
15. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
16. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M et al (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683-6693
17. Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC, Reifenberger G (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501-507
18. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW et al (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218:172-181
19. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748-754
20. Geisbrecht BV, Gould SJ (1999) The human PICD gene encodes a cytoplasmic and peroxisomal NADP(1)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527-30533
21. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38
22. Gupta R, Webb-Myers R, Flanagan S, Buckland ME (2011) Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 64:835-844
23. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74-89
24. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold- Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469-474
25. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
26. Hasselblatt M, Riesmeier B, Lechtape B, Brentrup A, Stummer W, Albert FK, Sepehrnia A, Ebel H, Gerss J, Paulus W (2011) BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 37:803-806
27. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine- DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874
28. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
29. Heimberger AB, Sampson JH (2009) The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 9:1087-1098
30. Horbinski C, Hamilton RL, Nikiforov Y et al (2010a) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119:641-649
31. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN (2010b) Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 12:487-492
32. Horbinski C, Miller CR, Perry A (2011) Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 21:57-73
33. Horbinski C, Nikiforova MN, Hagenkord JM, Hamilton RL, Pollack IF (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14:777-789
34. Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107-112
35. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347
36. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483-487
37. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A et al (2009) Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 101:722-733
38. Jeuken JW, Wesseling P (2010) MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol 222:324-328
39. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673-8677
40. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives toKIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28: 2119-2123
41. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69:1799-1811
42. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 406:608-613
43. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-551
44. Labussiere M, Idbaih A, Wang XW et al (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886-1890
45. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW (2002) Cytosolic NADP(1)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32:1185-1196
46. Li G, Wong AJ (2008) EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines 7:977-985
47. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) World Health Organization classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon, pp 41-43
48. Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38:271-291
49. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
50. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22:8835-8844
51. Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135:558-568
52. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
53. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235-2241
54. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
55. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173
56. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ et al (2006) O6 -methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol 24:3431-3437
57. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC et al (2008) Anti-O6-methylguaninemethyltransferase (MGMT)immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
58. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342-1350
59. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932-941
60. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567-584
61. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J et al (2009) MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45:146-153
62. Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
63. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold- Mende C et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extracerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405
64. Setty P, Gessi M, Waha A, Hammes J, El-Maarri O, Pietsch T, Waha A (2011) Sensitive determination of BRAF copy number in clinical samples by pyrosequencing. Diagn Mol Pathol 20: 148-157
65. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970
66. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
67. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606
68. Tannapfel A, Sommerer F, Benicke M et al (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712
69. Thompson CB (2009) Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 360:813-815
70. Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V et al (2011) Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 13:669-677
71. Trost D, Ehrler M, Fimmers R, Felsberg J, Sabel MC, Kirsch L et al (2007) Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer 120:2368-2376
72. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722
73. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604
74. van den Bent MJ, Hoang-Xuan K, Brandes AA, Kros JM, Kouwenhoven MCM, Taphoorn M et al (2012) Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol 30(18 Suppl):2
75. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
76. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74-87
77. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867
78. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880
79. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715
80. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30
81. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
82. Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67:1-15
83. Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H (2009) Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32:21-29
84. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al (2009) Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324:261-265